Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Furmonertinib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ArriVent BioPharma Reports First Quarter 2024 Financial Results
    ArriVent BioPharma Reports First Quarter 2024 Financial Results

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877780/0/en/ArriVent-BioPharma-Reports-First-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    InnoCare Announces of First Dosing of the Combination of ICP-189 & Furmonertinib
    InnoCare Announces of First Dosing of the Combination of ICP-189 & Furmonertinib

    28 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240328167713/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib
    ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib

    30 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/30/2768968/0/en/ArriVent-Receives-FDA-Breakthrough-Therapy-Designation-for-Furmonertinib-for-First-Line-Treatment-of-Advanced-or-Metastatic-Non-Small-Cell-Lung-Cancer-with-EGFR-Exon-20-Insertion-M.html

    GLOBENEWSWIRE
    30 Oct 2023
    Share Share
    InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189
    InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189

    13 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230913778402/en

    BUSINESSWIRE
    13 Sep 2023
    Share Share